Comparative Pharmacology
Head-to-head clinical analysis: DEPAKOTE CP versus DEPAKOTE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKOTE CP versus DEPAKOTE ER.
DEPAKOTE CP vs DEPAKOTE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valproate increases GABA concentration in the brain by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase. It also blocks voltage-gated sodium channels and T-type calcium channels.
Increases GABAergic activity by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase; blocks voltage-gated sodium and T-type calcium channels; reduces glutamate release.
250-500 mg orally twice daily, titrated by 250 mg/day every 3-7 days; maximum 60 mg/kg/day. Target trough serum concentration: 50-100 mcg/mL.
500-1000 mg orally once daily; usual maximum dose 60 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life is 9-16 hours (mean ~12 hours) in adults; prolonged in hepatic impairment, elderly, and neonates.
Terminal elimination half-life is approximately 20 hours (range 10-60 hours); clinical context: extended-release formulation allows once-daily dosing, steady-state achieved in 4-5 days
Renal: 30-50% as glucuronide conjugates, 3% as unchanged drug; fecal: minimal; less than 3% excreted in bile.
Primarily renal (30-50% as glucuronide conjugates, <3% as unchanged drug); minor fecal (10-20%)
Category C
Category C
Anticonvulsant
Anticonvulsant